Stockscreener 앱 받기
81.36
0.93%
-0.76
시간 외 거래:
81.25
-0.11
-0.14%
전일 마감가:
$82.12
열려 있는:
$82.04
하루 거래량:
528.54K
Relative Volume:
0.66
시가총액:
$5.56B
수익:
$189.76M
순이익/손실:
$-196.54M
주가수익비율:
-26.17
EPS:
-3.1087
순현금흐름:
$-156.63M
1주 성능:
-4.52%
1개월 성능:
-6.45%
6개월 성능:
-28.48%
1년 성능:
+24.80%
1일 변동 폭
$81.24
$84.00
1주일 범위
$80.06
$87.66
52주 변동 폭
$55.31
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
명칭
Rhythm Pharmaceuticals Inc
전화
857-264-4280
주소
222 BERKELEY STREET, BOSTON, MA
Compare RYTM vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
81.36 | 5.75B | 189.76M | -196.54M | -156.63M | -3.1087 |
VRTX
Vertex Pharmaceuticals Inc
|
427.38 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
707.06 | 76.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
781.72 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.49 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
295.27 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-19 | 개시 | RBC Capital Mkts | Outperform |
| 2025-11-25 | 개시 | Citigroup | Buy |
| 2025-11-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-07-07 | 개시 | Leerink Partners | Outperform |
| 2025-04-07 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-03-05 | 재개 | Stifel | Buy |
| 2025-01-02 | 개시 | Jefferies | Buy |
| 2024-12-20 | 개시 | Oppenheimer | Outperform |
| 2024-10-21 | 개시 | Guggenheim | Buy |
| 2024-09-18 | 개시 | H.C. Wainwright | Buy |
| 2024-09-17 | 개시 | JMP Securities | Mkt Outperform |
| 2024-05-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-01-18 | 재개 | Canaccord Genuity | Buy |
| 2022-08-08 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-05 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-06-17 | 재확인 | Needham | Buy |
| 2022-03-02 | 재개 | Stifel | Buy |
| 2022-02-17 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | 재개 | Goldman | Neutral |
| 2021-08-04 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-08-04 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-01-08 | 개시 | Goldman | Sell |
| 2019-07-12 | 업그레이드 | Stifel | Hold → Buy |
| 2019-07-08 | 개시 | Canaccord Genuity | Buy |
| 2019-03-13 | 개시 | Ladenburg Thalmann | Buy |
| 2018-09-07 | 재개 | Morgan Stanley | Overweight |
| 2018-06-25 | 재확인 | Needham | Buy |
| 2018-06-15 | 재확인 | Needham | Buy |
| 2017-10-30 | 개시 | BofA/Merrill | Buy |
| 2017-10-30 | 개시 | Needham | Buy |
모두보기
Rhythm Pharmaceuticals Inc 주식(RYTM)의 최신 뉴스
Vanguard Capital Management (RYTM) files Schedule 13G for 5.02% stake - Stock Titan
[ARS] RHYTHM PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Board elections and Say-on-Pay on deck for Rhythm Pharmaceuticals (NASDAQ: RYTM) - Stock Titan
Rhythm pharmaceuticals outlines Q3 2025 filing for acquired hypothalamic obesity treatment - MSN
Rhythm Pharmaceuticals initiated with Buy at Citi on Imcivree's potential - MSN
Analysts Estimate Rhythm Pharmaceuticals, Inc. (RYTM) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Rhythm Pharma wins EU backing to expand Imcivree label - MSN
Rhythm Pharmaceuticals (RYTM): Precision Obesity Pivot Grabs Headlines - Insider Monkey
Rhythm Pharmaceuticals, Inc. (RYTM): Investor Outlook Reveals 60% Potential Upside In Biotech Sector - DirectorsTalk Interviews
RHYTHM PHARMACEUTICALS INC (RYTM) Fundamental Analysis & Valuation - ChartMill
Universal Beteiligungs und Servicegesellschaft mbH Increases Stock Holdings in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Is RYTM a Good Stock to Buy? Bearish Thesis on Rhythm Pharmaceuticals - HarianBasis.co
M&T Bank Corp Invests $9.20 Million in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Is Rhythm Pharmaceuticals, Inc. (RYTM) A Good Stock To Buy Now? - Insider Monkey
RYTM Technical Analysis | Trend, Signals & Chart Patterns | RHYTHM PHARMACEUTICALS INC (NASDAQ:RYTM) - ChartMill
RYTM (Rhythm Pharmaceuticals) tops Q4 2025 EPS estimates, posts 45.8 percent year-over-year revenue growth, shares dip 1.09 percent.Popular Market Picks - Xã Thanh Hà
Rhythm Pharmaceuticals (RYTM) Stock: Mistakes to Avoid (Technical Strength) 2026-04-20Crowd Sentiment Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Rhythm Pharmaceuticals (NASDAQ:RYTM) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Needham Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $130 - 富途牛牛
BofA Securities Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating - 富途牛牛
Goldman Sachs Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $158 - Moomoo
Assessing Rhythm Pharmaceuticals (RYTM) Valuation After A Recent Share Price Pullback - Sahm
Is Rhythm Pharmaceuticals (RYTM) Still Attractive After A 48.9% One‑Year Share Price Gain - Sahm
Avoiding Lag: Real-Time Signals in (RYTM) Movement - Stock Traders Daily
Rhythm Pharmaceuticals (RYTM) reports phase 3 EMANATE trial topline results for setmelanotide - MSN
Wall Street Zen Upgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) to Hold - MarketBeat
Risk Analysis: Is Rhythm Pharmaceuticals Inc gaining market share2026 Outlook & Reliable Price Action Trade Plans - baoquankhu1.vn
Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026 - The Manila Times
Rhythm sets May 5 earnings call, CFO due at Needham event - Stock Titan
Should I trade or invest in Rhythm Pharmaceuticals Inc2026 Fundamental Recap & Real-Time Buy Signal Alerts - baoquankhu1.vn
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Why Rhythm Pharmaceuticals (RYTM) Is Up 12.6% After EU IMCIVREE Expansion Boost and Board Refresh – And What's Next - Sahm
Dip Buying: Is Rhythm Pharmaceuticals Inc currently under institutional pressureGap Down & Weekly Breakout Stock Alerts - baoquankhu1.vn
Momentum Shift: What are Rhythm Pharmaceuticals Incs growth leversWeekly Trade Analysis & Weekly Setup with High ROI Potential - baoquankhu1.vn
RBC Capital Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $136 - Moomoo
Rhythm Pharmaceuticals, Inc. (RYTM) stock price, news, quote and history - Yahoo Finance UK
A Look At Rhythm Pharmaceuticals (RYTM) Valuation After IMCIVREE Approval Expands Obesity Treatment Reach - Sahm
Rhythm Pharma down after late-stage trial setback for lead asset in rare obesity disorders - MSN
How The Rhythm Pharmaceuticals (RYTM) Story Is Evolving After EMANATE And Imcivree Developments - Yahoo Finance
Rhythm Pharmaceuticals Setmelanotide FDA Approval, Company Details, and XBRL Filing Information - Minichart
Rhythm Pharmaceuticals Announces Changes to Board of Directors - Sahm
Rhythm Pharmaceuticals adds Kim Popovits to board of directors By Investing.com - Investing.com Australia
Rhythm Pharmaceuticals (RYTM) EVP converts RSUs, now holding 66,030 shares - Stock Titan
RHYTHM (RYTM) director receives 6,808 RSUs and 10,257 stock options - Stock Titan
Rhythm Pharmaceuticals (RYTM) director Kimberly Popovits files initial Form 3 - Stock Titan
Kim Popovits joins Rhythm (NASDAQ: RYTM) board as Ed Mathers exits - Stock Titan
Rhythm Pharmaceuticals, Inc. Announces Changes in Board of Directors - MarketScreener
Rhythm Pharmaceuticals adds Kim Popovits to board of directors - Investing.com
Rhythm Pharmaceuticals Inc (RYTM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.67%
자본화:
|
볼륨(24시간):